No Data
No Data
JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $90
LifeSci Capital Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $100
BofA Securities Maintains Janux Therapeutics(JANX.US) With Buy Rating, Announces Target Price $65
Janux Therapeutics Down Over 12%, on Pace for Largest Percent Decrease Since August 2022 -- Data Talk
Buy Rating for Janux Therapeutics Inc: Promising Clinical Trial Results and Positive Outlook for JANX007
William Blair Maintains Janux Therapeutics(JANX.US) With Buy Rating